Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE – Research Report) today and set a price target of $650.00. The company’s shares closed yesterday at $617.95.
Wiederhorn covers the Healthcare sector, focusing on stocks such as Addus Homecare, Chemed, and Community Health. According to TipRanks, Wiederhorn has an average return of 15.6% and a 68.07% success rate on recommended stocks.
Chemed has an analyst consensus of Strong Buy, with a price target consensus of $690.00, an 11.66% upside from current levels. In a report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $708.00 price target.
CHE market cap is currently $9.33B and has a P/E ratio of 34.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chemed (CHE) Company Description:
Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the following segments: VITAS and Roto-Rooter. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.
